IGMS

6.90

2.13% -0.15

Handel nachbörslich: 6.90

Igm Biosciences Inc (IGMS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$7.05

Offen:

$6.88

24-Stunden-Volumen:

419.38K

Relative Volume:

1.53

Marktkapitalisierung:

$410.30M

Einnahmen:

$2.91M

Nettoeinkommen (Verlust:

$-220.40M

KGV:

-1.3093

EPS:

-5.27

Netto-Cashflow:

$-176.15M

1W Leistung:

-3.77%

1M Leistung:

-29.34%

6M Leistung:

+5.99%

1J Leistung:

-12.21%

1-Tages-Spanne:

$6.755

$7.50

1-Wochen-Bereich:

$6.755

$7.86

52-Wochen-Spanne:

$6.1721

$22.50

Igm Biosciences Inc Stock (IGMS) Company Profile

Firmenname

Igm Biosciences Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

650-965-7873

Adresse

325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW

Mitarbeiter

198

Twitter

Nächster Verdiensttermin

2024-11-11

Neueste SEC-Einreichungen

IGMS's Discussions on Twitter

Vergleichen Sie IGMS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IGMS Igm Biosciences Inc	6.90	410.30M	2.91M	-220.40M	-176.15M	-3.64
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-06	Eingeleitet	BMO Capital Markets	Outperform
2024-10-01	Herabstufung	JP Morgan	Neutral → Underweight
2024-10-01	Herabstufung	Truist	Buy → Hold
2024-02-09	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2023-12-15	Herabstufung	BofA Securities	Buy → Neutral
2023-12-07	Herabstufung	H.C. Wainwright	Buy → Neutral
2022-11-09	Fortgesetzt	Jefferies	Buy
2022-10-17	Eingeleitet	JP Morgan	Neutral
2022-08-29	Eingeleitet	BofA Securities	Buy
2021-12-13	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2021-11-05	Hochstufung	Wedbush	Neutral → Outperform
2021-08-26	Eingeleitet	Morgan Stanley	Overweight
2021-01-29	Eingeleitet	RBC Capital Mkts	Outperform
2021-01-19	Bestätigt	H.C. Wainwright	Buy
2020-12-22	Herabstufung	Wedbush	Outperform → Neutral
2020-07-17	Eingeleitet	Robert W. Baird	Outperform
2020-07-01	Eingeleitet	H.C. Wainwright	Buy
2020-05-28	Eingeleitet	SunTrust	Buy
2020-04-22	Eingeleitet	Wedbush	Outperform
2019-10-14	Eingeleitet	Guggenheim	Buy
2019-10-14	Eingeleitet	Jefferies	Buy
2019-10-14	Eingeleitet	Piper Jaffray	Overweight
2019-10-14	Eingeleitet	Stifel	Buy

Alle ansehen

Igm Biosciences Inc Aktie (IGMS) Neueste Nachrichten

Dec 18, 2024

IGM Biosciences, Inc. (NASDAQ:IGMS) CEO Mary Beth Harler Sells 1,708 Shares - MarketBeat

Dec 18, 2024

Igm biosciences principal accounting officer sells shares for $4,031 - Investing.com

Dec 18, 2024

Igm biosciences CEO sells $12,775 in stock - Investing.com

Dec 18, 2024

IGM Biosciences chief business officer sells shares worth $7,951 By Investing.com - Investing.com Canada

Dec 18, 2024

IGM Biosciences (NASDAQ:IGMS shareholders incur further losses as stock declines 21% this week, taking five-year losses to 84% - Simply Wall St

Dec 18, 2024

Brokerages Set IGM Biosciences, Inc. (NASDAQ:IGMS) Target Price at $17.75 - Defense World

Dec 18, 2024

Dec 15, 2024

IGM Biosciences, Inc. (NASDAQ:IGMS) Receives $17.75 Average Target Price from Analysts - MarketBeat

Dec 15, 2024

Dec 14, 2024

IGM Biosciences' SWOT analysis: stock pivot to autoimmune focus sparks analyst optimism - Investing.com Australia

Dec 14, 2024

IGM Biosciences' SWOT analysis: stock pivot to autoimmune focus sparks analyst optimism By Investing.com - Investing.com South Africa

Dec 14, 2024

Dec 08, 2024

BMO Capital Markets Begins Coverage on IGM Biosciences (NASDAQ:IGMS) - Defense World

Dec 08, 2024

IGM Biosciences (NASDAQ:IGMS) Shares Gap Up – Here’s What Happened - Defense World

Dec 08, 2024

Dec 07, 2024

IGM Biosciences (NASDAQ:IGMS) Shares Gap UpStill a Buy? - MarketBeat

Dec 07, 2024

BMO Capital Initiates Coverage of IGM Biosciences (IGMS) with Outperform Recommendation - MSN

Dec 07, 2024

Dec 06, 2024

IGM Biosciences (NASDAQ:IGMS) Coverage Initiated by Analysts at BMO Capital Markets - MarketBeat

Dec 06, 2024

Dec 05, 2024

BMO sets $21 target for IGM Biosciences with Outperform rating By Investing.com - Investing.com UK

Dec 05, 2024

Dec 04, 2024

IGM Biosciences: Dizzying Number Of Pivots (NASDAQ:IGMS) - Seeking Alpha

Dec 04, 2024

Dec 02, 2024

Quest Partners LLC Decreases Stock Position in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World

Dec 02, 2024

Nov 30, 2024

Brokerages Set IGM Biosciences, Inc. (NASDAQ:IGMS) Price Target at $16.13 - MarketBeat

Nov 20, 2024

IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World

Nov 20, 2024

Nov 15, 2024

Will Imvotamab Data Propel IGM Biosciences To New Heights In 2025? - RTTNews

Nov 15, 2024

Nov 13, 2024

How To Trade (IGMS) - Stock Traders Daily

Nov 13, 2024

FMR LLC Increases Stake in IGM Biosciences Inc - GuruFocus.com

Nov 13, 2024

Nov 12, 2024

IGM Biosciences Insiders Who Sold Avert US$165m Market Cap Dip - Simply Wall St

Nov 12, 2024

Nov 11, 2024

Biotech firm backs off its focus on oncology research - The Business Journals

Nov 11, 2024

IGM Biosciences (NASDAQ:IGMS) Given New $27.00 Price Target at Stifel Nicolaus - MarketBeat

Nov 11, 2024

Igm Biosciences: Navigating Financial Challenges Amidst Early-Stage Antibody Development - MSN

Nov 11, 2024

Nov 10, 2024

IGM Biosciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 10, 2024

Nov 09, 2024

IGM Biosciences (NASDAQ:IGMS) Shares Down 7.8%Here's Why - MarketBeat

Nov 09, 2024

Nov 08, 2024